Affilogic is a private biotech company specialised in discovering and developing Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

These affinity proteins are potent antibody-mimetics, exhibiting a high affinity and specificity for capture, targeting and interacting with biomolecules. Each Nanofitin® is 20 times smaller than an antibody (7 kDa) and demonstrates hyper stability. Nanofitins are easily combined with each other, antibodies and other biomolecules by simple, rapid and proven methods to design an ideal targeted molecule.

Affilogic has designed Nanofitins® against 100+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (virus-like particles, bacteria, whole cells).

Affilogic wants to hear from you!

J.P. Morgan Healthcare Conference

J.P. Morgan Healthcare Conference

Virtually meet us at JP Morgan Healthcare Conference
January 10-13, 2022

Visit the event website

CPhI Worldwide 2021

CPhI Worldwide 2021

Meet us at CPhI 2021
@ Milan, Italy
November 9-11, 2021

Visit the event website

Competitive Advantages

Nanofitins® Biotherapeutics

Partnering Strategy